Raynaud phenomenon, scleroderma, overlap syndromes and other fibrosing syndromesLocalized sclerodermaLaxer, Ronald Ma; Zulian, FrancescobAuthor Information aDepartment of Paediatrics and Medicine, University of Toronto, Vice President, Education and Quality, The Hospital for Sick Children, Toronto, Canada bDivision of Paediatric Rheumatology, Department of Paediatrics, University of Padova, Padova, Italy Correspondence to Ronald M. Laxer, Professor of Paediatrics and Medicine, University of Toronto, Vice President, Education and Quality, The Hospital for Sick Children, Room 1410, 555 University Avenue, Toronto, Ontario, Canada Tel: +1 416 813 5709; e-mail: [email protected] Current Opinion in Rheumatology: November 2006 - Volume 18 - Issue 6 - p 606-613 doi: 10.1097/01.bor.0000245727.40630.c3 Buy Metrics Abstract Purpose of review Localized scleroderma, also known as morphoea, has a variety of clinical manifestations that can include systemic involvement. Early recognition, diagnosis and treatment may improve the long-term outcome. Recent findings A large multicentre study coordinated by the Pediatric Rheumatology European Society has yielded important information on the epidemiology and clinical manifestations of juvenile localized scleroderma, especially as it pertains to systemic manifestations. Previous results using methotrexate and corticosteroids have been confirmed. Studies on phototherapy have also demonstrated efficacy. A new immunomodulator, imiquimod, has shown promise in an initial case series. Summary Studies over the past year highlight the wide range of extracutaneous manifestations and different forms of localized scleroderma and suggest that treatment may be beneficial. © 2006 Lippincott Williams & Wilkins, Inc.